<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859819</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-157</org_study_id>
    <secondary_id>L 10,753</secondary_id>
    <nct_id>NCT01859819</nct_id>
  </id_info>
  <brief_title>Treatment for Advanced B-Cell Lymphoma</brief_title>
  <acronym>REBOOT</acronym>
  <official_title>Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To safely reduce the burden of therapy in children, adolescents and young adults with mature&#xD;
      B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT&#xD;
      Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and reducing the dose of anthracycline&#xD;
      (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy&#xD;
      backbone (Immunochemotherapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if disease response rate will improve with this combination of therapy.</measure>
    <time_frame>1 year</time_frame>
    <description>To determine if the addition of intrathecal ([IT] [Depocyt®]) and reduction of standard IT dosing and the reduction of anthracycline exposure (doxorubicin) (60%) within the ANHL01P1 FAB/LMB B4 + Rituximab chemoimmunotherapy backbone in children, adolescents and young adults with good risk CD20+ mature B-NHL (Stage I and II unresected and Stage III/IV with LDH &lt; 2 UNL) will result in similar response rates compared to historical controls (Subgroup I).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if the combination of IT Depocyte®, Rituximab and FAB Chemotherapy is safe.</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the safety and efficacy of reduction of IT therapy and substitution with L-ARA-C (Depocyte®) within ANHL01P1 FAB/LMB Group C1 plus rituximab chemotherapy backbone in children, adolescents and young adults with advanced risk de-novo mature B-NHL (Group C BM±CNS) (Subgroup II) as measured by reported serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <condition>Burkitt's Lymphoma</condition>
  <condition>High Grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH &lt;2 X ULN.&#xD;
REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C, CNS negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-novo Mature CD 20 + B-ALL (&gt; 25% Bone marrow blasts) without CNS involvement.&#xD;
REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C, CNS Positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-novo Mature CD 20 + B-NHL with CNS involvement:&#xD;
Any L3 blasts in CSF&#xD;
Cranial nerve palsy (if not explained by extracranial tumor)&#xD;
Clinical spinal cord compression&#xD;
Isolated intracerebral mass&#xD;
Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C, CNS Positive</arm_group_label>
    <arm_group_label>Group C, CNS negative</arm_group_label>
    <other_name>RITUXAN®, IDEC-C2B8) NSC #687451, IND #10385</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IT Cytarabine</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C, CNS Positive</arm_group_label>
    <arm_group_label>Group C, CNS negative</arm_group_label>
    <other_name>DEPOCYT® (Cytarabine Liposome Injection)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed mature B-lineage (CD20 positive) Leukemia/Lymphoma&#xD;
&#xD;
          -  1. Diffuse Large Cell Lymphoma (NOT primary mediastinal B-cell lymphoma) -2. Burkitt's&#xD;
             Lymphoma&#xD;
&#xD;
          -  3. High Grade B-cell Lymphoma---Burkitt's like.&#xD;
&#xD;
        B-Cell Anaplastic Large cell Ki 1 positive lymphomas, Primary Mediastinal B-Cell Lymphoma&#xD;
        (PMBL), and B-Lymphoblastic lymphomas are ineligible.&#xD;
&#xD;
        No previous chemotherapy. Patients who have received emergency irradiation and/or steroid&#xD;
        therapy will be eligible ONLY if started on protocol therapy not more than 72 hours from&#xD;
        the start of radiotherapy or steroids. Bone marrow and cerebrospinal fluid MUST be obtained&#xD;
        before steroids are given for patient to be eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with newly diagnosed Group A (low risk) lymphoma. Patients with Group B&#xD;
             (intermediate risk) if classified as Murphy Stage III/IV and diagnostic LDH &gt; 2 XULN&#xD;
             and patients with primary mediastinal B-cell lymphoma (PMBL).&#xD;
&#xD;
          -  Patients who have received any steroids in the week prior to diagnosis except as&#xD;
             stated in Section 4.1.4 of the protocol.&#xD;
&#xD;
          -  No congenital or acquired immune deficiency. These patients are excluded due to the&#xD;
             expected intense immunosuppression, increased risk of opportunistic infections, and&#xD;
             higher expected septic death rate in this subgroup of patients with this proposed&#xD;
             therapy.&#xD;
&#xD;
          -  No prior solid organ transplantation.&#xD;
&#xD;
          -  Patients with previous malignancies that have been treated with systemic chemotherapy&#xD;
             with alkylator or anthracycline therapy. The latter group of patients are excluded due&#xD;
             to an expected increase in late effects (eg. late cardiac toxicity, secondary&#xD;
             malignancies, sterility, etc.).&#xD;
&#xD;
          -  Patients with known G6PD deficiency are NOT ELIGIBLE for Rasburicase therapy. Patients&#xD;
             with G6PD deficiency should be treated with alkalinization, IV hydration and po and/or&#xD;
             IV allopurinol during the reduction phase (COP).&#xD;
&#xD;
        4.2.6 Patients with serious (sepsis, pneumonia, etc..) proven or suspected infections at&#xD;
        diagnosis will be excluded.&#xD;
&#xD;
        4.2.7 Pregnancy or Breast-Feeding: No information is available regarding human fetal or&#xD;
        teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal.&#xD;
        Males or females of reproductive potential may not participate unless they have agreed to&#xD;
        use an effective contraceptive method.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanton Goldman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical City Children's Hospital, Dallas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia. 2021 Oct;35(10):2994-2997. doi: 10.1038/s41375-021-01256-8. Epub 2021 May 3.</citation>
    <PMID>33941850</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Lymphoma (NOT primary mediastinal B-cell lymphoma)</keyword>
  <keyword>B-Cell---Burkitt's like</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Liposomal ARA-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

